Advanced search
Publication Cover
Hematology Volume 28, 2023 - Issue 1
Submit an article Journal homepage
1,787
Views
0
CrossRef citations to date
0
Altmetric
Research Article

The utility of testing erythropoietin level in polycythemia diagnosis

Abdellatif Ismaila Department of Internal Medicine, University of Maryland Medical Center Midtown Campus, Baltimore, MD, USACorrespondence[email protected]
ORCID Iconhttps://orcid.org/0009-0006-1854-4569View further author information
ORCID Icon,
Elmustafa Abdallab Department of Medicine, Hamad Medical Corporation, Doha, QatarView further author information
,
Ali Aqelb Department of Medicine, Hamad Medical Corporation, Doha, QatarView further author information
,
Abdalla Fadulb Department of Medicine, Hamad Medical Corporation, Doha, QatarView further author information
,
Ashraf Ahmedb Department of Medicine, Hamad Medical Corporation, Doha, QatarView further author information
,
Ahmed Alsayedb Department of Medicine, Hamad Medical Corporation, Doha, QatarView further author information
,
Muzamil Musab Department of Medicine, Hamad Medical Corporation, Doha, QatarView further author information
&
Mohamed A. Yassinc Department of Medical Oncology /Hematology, National Center for Cancer Care and Research, Hamad Medical Corporation, Doha, QatarView further author information
 show all
Article: 2269510 | Received 21 Aug 2023, Accepted 07 Oct 2023, Published online: 16 Oct 2023

References

  • Pillai AA, Fazal S, Mukkamalla SKR, et al. Polycythemia. [Updated 2023 May 20]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK526081/.
  • Barbui T, Thiele J, Gisslinger H, et al. The 2016 WHO classification and diagnostic criteria for myeloproliferative neoplasms: document summary and in-depth discussion. Blood Cancer J. 2018;8(2):15. doi: 10.1038/s41408-018-0054-y
  • Thiele J, Kvasnicka HM. The 2008 WHO diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis. Curr Hematol Malig Rep. 2009;4(1):33–40. doi: 10.1007/s11899-009-0005-6
  • Lippert E, Boissinot M, Kralovics R, et al. The JAK2-V617F mutation is frequently present at diagnosis in patients with essential thrombocythemia and polycythemia vera. Blood. 2006;108(6):1865–1867. doi: 10.1182/blood-2006-01-013540
  • Luque Paz D, Jouanneau-Courville R, Riou J, et al. Leukemic evolution of polycythemia vera and essential thrombocythemia: genomic profiles predict time to transformation. Blood Adv. 2020;4(19):4887–4897. doi: 10.1182/bloodadvances.2020002271
  • Stuart BJ, Viera AJ. Polycythemia vera. Am Fam Physician. 2004;69(9):2139–2144.
  • Radia D, Geyer HL. Management of symptoms in polycythemia vera and essential thrombocythemia patients. Hematology Am Soc Hematol Educ Program. 2015;2015:340–348. doi: 10.1182/asheducation-2015.1.340
  • Lurlo A, Cattaneo D, Gianelli U. Blast transformation in myeloproliferative neoplasms: risk factors, biological findings, and targeted therapeutic options. Int J Mol Sci. 2019;20(8):1839.
  • Kim JY, Woo IS, Yoo SH, et al. JAK2 V617F-positive polycythemia vera accompanied by renal artery stenosis. Blood Res. 2014;49(4):283–285. doi: 10.5045/br.2014.49.4.283
  • Davila-Gonzalez D, Barrios-Ruiz A, Fountain E, et al. Diagnostic performance of erythropoietin levels in polycythemia vera: experience at a comprehensive cancer center. Clin Lymphoma Myeloma Leuk. 2021;21(4):224–229. doi: 10.1016/j.clml.2020.11.002
  • Lupak O, Han X, Xie P, et al. The role of a low erythropoietin level for the polycythemia vera diagnosis. Blood Cells Mol Dis. 2020;80:102355. doi: 10.1016/j.bcmd.2019.102355
  • Michiels JJ, Bernema Z, Van Bockstaele D, et al. Current diagnostic criteria for the chronic myeloproliferative disorders (MPD) essential thrombocythemia (ET), polycythemia vera (PV) and chronic idiopathic myelofibrosis (CIMF). Pathol Biol (Paris). 2007;55(2):92–104. doi: 10.1016/j.patbio.2006.06.002
  • Krečak I, Holik H, Morić Perić M, et al. High platelet-to-lymphocyte ratio may differentiate polycythemia vera from secondary polycythemia. Wien Klin Wochenschr. 2022;134(11–12):483–486. doi: 10.1007/s00508-022-02027-w
  • Barbui T, Thiele J, Vannucchi AM, et al. Rationale for revision and proposed changes of the WHO diagnostic criteria for polycythemia vera, essential thrombocythemia and primary myelofibrosis. Blood Cancer J. 2015;5(8):e337. doi: 10.1038/bcj.2015.64
  • Schoener B, Borger J. Erythropoietin stimulating agents. [Updated 2023 Mar 11]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK536997/
  • Thurmes PJ, Steensma DP. Elevated serum erythropoietin levels in patients with Budd-Chiari syndrome secondary to polycythemia vera: clinical implications for the role of JAK2 mutation analysis. Eur J Haematol. 2006;77(1):57–60. doi: 10.1111/j.1600-0609.2006.00667.x

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.